[LINK] AstraZeneca more effective against Delta?

[Stephen Loosley]

Thanks for the interesting post Marghanita.

Here’s an in-depth summary of the Bahrain study:

“The percentage of deaths among all PCR positive post-vaccination COVID-19 cases among recipients of Sinopharm was 0.46% (i.e, 112 deaths)  versus 0.15% for Pfizer/BioNtech  (i.e., 3 deaths)  and 0.03% for AZ / Covishield  (1 death).  This trend was consistent for all COVID-19 events.  (Table 1 Page 10).”


ABSTRACT Summary

Here we present an analysis of COVID-19 related outcomes from Bahrain, a country with a total population of 1.501 million, where four vaccines were deployed (total vaccinated =1,003,960), including Astra-Zeneca (AZ / Covishield), Pfizer / BioNtech, Sinopharm and Sputnik V.

Between December 2020 and July 2021, there were 569,054 individuals vaccinated with Sinopharm, and
184,526 with Sputnik, and 73,765 with AstraZeneca (AZ / Covishield) and 169,058 with Pfizer/BioNtech
vaccines, while 245,876 were used as the unvaccinated case-control cohort (Fig 1 Page 10). These unvaccinated
included travellers and individuals undergoing random tests in areas of high population density.

COVID-19 Outcomes

There were a total of 180,840 PCR positive COVID-19 cases identified among all individuals, with 134,728 among those 18 years and older. There were 13,105 hospitalizations, including 1,636 ICU admissions, and a total of 1,030 deaths.

We assessed COVID-19 hospitalizations, ICU admissions and deaths by vaccination status. We further examined the data by age, for those >50 versus < 50 years of age, taking into account the known increase in risk of COVID-19 related morbidity and mortality among those >50 years of age. In order to limit multiple comparisons, we did paired testing among these groups: Unvaccinated vs Sinopharm, Unvaccinated vs Pfizer/BioNtech, Unvaccinated vs AZ / Covishield, and Unvaccinated vs Sputnik V.

Research Findings

Using pairwise comparisons between unvaccinated individuals (> 50 and <50 years), we found significantly higher % of
hospitalization, ICU admissions and deaths in the unvaccinated group compared to the vaccinated group for all four vaccines (Table 1 Page 10).

The percent of deaths among all COVID-19 cases in unvaccinated people >50 years of age was 3.8-fold higher compared to the Sinopharm, and approximately 7.5-fold higher than the Sputnik V vaccine recipients.  There were no deaths reported in the AZ / Covishield vaccinated group.

In patients <50 years, the percent of death among all COVID-19 cases in unvaccinated people were 8.1-fold higher compared to Sinopharm vaccine recipients. There were no deaths reported in this age cohort in Sputnik V and Pfizer/BioNtech vaccine recipients, and 1 death among the AZ / Covishield vaccine recipients (Table 1 Page 10).

The percentage of deaths among all PCR positive post-vaccination COVID-19 cases among recipients of the Sinopharm vaccine was 0.46% (i.e, 112 deaths)  versus 0.15% for Pfizer/BioNtech (i.e., 3 deaths)  and 0.03% for AZ / Covishield (1 death).     This trend was consistent for all COVID-19 events, i.e., infection, hospitalization, ICU admission and death.
(Table 1 Page 10).

The study: https://assets.researchsquare.com/files/rs-828021/v1_covered.pdf?c=1629920029